Delving into the Latest Updates on Propranolol Hydrochloride with Synapse

Overview

Basic Info

SummaryPropranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.. This drug is used to treat various conditions, including hypertension, angina pectoris, atrial fibrillation, atrial premature complexes, bradycardia, and tachycardia. AstraZeneca developed Propranolol Hydrochloride, which received approval on August 18th, 1966. Propranolol Hydrochloride works by blocking the sympathetic nervous system's action on the heart and blood vessels, which ultimately results in a reduction in heart rate, blood pressure, and oxygen demand. Although Propranolol Hydrochloride can be effective in managing these conditions, it can also cause side effects such as fatigue, dizziness, and depression, and as such, it should only be taken under the guidance of a healthcare provider. Careful monitoring of patients for any adverse effects is also necessary. Overall, Propranolol Hydrochloride is a useful medication for managing heart-related conditions, but each individual patient's case should be carefully considered before use.

Drug Type

Small molecule drug

Synonyms

1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, beta-Propranolol

+ [38]

Target

β-adrenoceptors

Action

antagonists

Mechanism

β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [1]

Active Indication

HypoxiaHemangiomaMigraine Disorders+ [9]

Inactive Indication

Capillary HemangiomaCardiomyopathy, HypertrophicEssential Tremor+ [1]

Originator Organization

AstraZeneca PLC

Active Organization

Pierre Fabre Médicament SASTaiyo Pharma Co., Ltd.Pierre Fabre Medicament Information

+ [6]

Inactive Organization

Pierre Fabre SAWyeth Pharmaceuticals LLC

License Organization

Pierre Fabre (Shanghai) Medical Technology Co., Ltd.

Wuhan Kefu New Drug Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (18 Aug 1966),

Angina PectorisAtrial FibrillationAtrial Premature Complexes+ [4]

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC16H22ClNO2

InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N

CAS Registry318-98-9

This goal of this study is to compare three medications used for migraine preventive treatment.
This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.
Research participants will:
* Be randomly assigned to one of the three medications.
* Provide information about their migraine pattern using a daily headache diary and during research visits.

Start Date01 Jul 2025

Sponsor / Collaborator

Mayo Clinic

[+3]

100 Clinical Results associated with Propranolol Hydrochloride

Login to view more data

100 Translational Medicine associated with Propranolol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Propranolol Hydrochloride

Login to view more data

51,579

Literatures (Medical) associated with Propranolol Hydrochloride

31 Dec 2025·European Journal of Psychotraumatology

Hippocampal connectivity changes after traumatic memory reactivation with propranolol for posttraumatic stress disorder: a randomized fMRI study

Article

Author: Leroy, A. ; Birmes, P. ; Vaiva, G. ; Jardri, R. ; Taib, S. ; Richaud, L. ; Loubinoux, I. ; Very, E. ; Bourcier, A. ; Roullet, P.

Background: Reactivation of traumatic memory under the influence of propranolol has shown encouraging clinical results in the treatment of posttraumatic stress disorder (PTSD), but the neural correlates remain unknown. To identify these correlates, we examined the changes in brain functional connectivity specifically associated with the influence of propranolol and their correlation with improvement in PTSD symptoms.Objectives: To identify resting-state functional connectivity (rs-FC) changes specifically associated with propranolol after a traumatic memory reactivation procedure (TMRP) in PTSD patients.Method: Thirty patients (50% of women) with PTSD were enrolled in a randomized controlled study comprised of six sessions of a traumatic memory reactivation procedure (TMRP) under the influence of propranolol (n = 16), compared to the same reactivation under a placebo (n = 14). Patients were scanned twice by functional magnetic resonance before and after treatment. Resting state functional connectivity (rs-FC) was compared across groups and over time.Results: Post versus pretreatment comparisons found an increase in rs-FC between the right hippocampus and the left parahippocampal gyrus in the propranolol group, but not in the placebo group. Symptom improvement in both groups were associated with an increase in rs-FC between the parahippocampal gyrus and both the supramarginal gyrus and the amygdala.Conclusions: During TMRP treatment, propranolol appears to constrain functional connectivity changes in the explicit memory brain system. These findings require further replication and exploration but could distinguish the effect of TMRP on the brain from other forms of PTSD psychotherapy.

31 Dec 2025·REDOX REPORT

Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation

Article

Author: Zhu, Guo-Qing ; Dai, Min ; Wang, Jing-Xiao ; Wang, Yi-Ming ; Dong, Hong-Ke ; Xu, Xiao-Yu ; Li, Xiu-Zhen

BACKGROUND:

Sympathetic overactivity is closely associated with vascular remodeling. Sympathetic fibers dominantly innervate the adventitia of arteries rather than tunica media. Vascular adventitial fibroblasts (VAFs) play crucial roles in vascular remodeling. However, the link between sympathetic overactivity and VAF proliferation and migration is unknown.

METHODS:

Primary VAFs were isolated from the thoracic aorta of spontaneously hypertensive rats and Wistar-Kyoto rats. Norepinephrine (NE) bitartrate monohydrate was applied to VAFs to simulate the sympathetic overactivity.

RESULTS:

NE increased NADPH oxidase (NOX) 2 expression and superoxide level, which were almost abolished by NOX2 inhibitor GSK2795039 or α-adrenoceptor antagonist prazosin, but not significantly affected by NOX1 inhibitor ML171, NOX4 inhibitor GLX351322 or β-adrenoceptor antagonist propranolol. Superoxide scavenger tempol or NOX2 inhibitor GSK2795039 attenuated NE-induced VAF proliferation and migration. NE promoted protein kinase C (PKC) phosphorylation and NFκB-p65 nuclear translocation. Either PKC inhibitor Go6983 or NFκB inhibitor BAY11-7082 attenuated NE-induced NOX activation, NOX2 upregulation, superoxide production, proliferation and migration.

CONCLUSION:

NE promotes oxidative stress by α-receptor/PKC/NFκB-mediated NOX2 upregulation, which contributes to proliferation and migration of VAFs.

01 Dec 2025·European Journal of Trauma and Emergency Surgery

Effects of early propranolol administration on mortality from severe, traumatic brain injury: a retrospective propensity score-matched registry study

Article

Author: Hong, Jinpyo ; Rizk, Elias ; Hallan, David R ; Jareczek, Francis J ; Park, Haejoe ; Bailey, David ; Stoltzfus, Mason T ; Freedman, Zachary

BACKGROUND:

The role of beta-blockers in severe, traumatic brain injury (TBI) management is debated. Severe TBI may elicit a surge of catecholamines, which has been associated with increased morbidity and mortality. We hypothesize administering propranolol, a non-selective beta-blocker, within 48 h of TBI will reduce patient mortality within 30 days of injury. The TriNetX database was leveraged to determine if administering a propranolol within 48 h of severe TBI improves outcomes within 30 days of injury.

METHODS:

The TriNetX Research Network was used to form two cohorts using retrospective data from 106,294,356 patient profiles from 9/10/2022, which included patients from years 2022 to 2022. The propranolol-receiving cohort included all patients who received the first-instance diagnosis of severe TBI (defined by a Glascow coma scale score of 3-8) and propranolol within 48 h of injury. The non-propranolol-receiving cohort included all patients with the same diagnosis of severe TBI but did not receive beta-blockers. The primary outcome of interest was mortality at 30 days. Secondary outcomes included gastrostomy tube placement, neurosurgical intervention in the form of craniotomy, craniectomy, burr hole drainage, seizure, and cardiac arrest.

RESULTS:

After propensity score-matching, 381 patients were identified for both cohorts. At 30 days post-severe TBI, 22.7% (84) of patients from the cohort that received propranolol, and 30.77% (116) from the cohort that did not, were deceased (OR 0.66), 95% CI [0.48, 0.92]), (p 0.01). TBI patients who received propranolol also had lower odds of requiring neurosurgical intervention, experience seizures, and cardiac arrest.

CONCLUSION:

The results of this study demonstrate significantly reduced mortality within 30 days of injury and fewer neurosurgical interventions, seizures, and episodes of cardiac arrest in severe TBI patients who received propranolol within 48 h of injury.

46

News (Medical) associated with Propranolol Hydrochloride

15 May 2025

·www.globenewswire.com

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 Brekiya autoinjector provides patients with the potential for sustained* pain relief† in a convenient, self-administered form.1,3,4 It contains the same medication (DHE) used in hospitals, now in a ready-to-use device.1,5 Brekiya autoinjector does not require refrigeration, assembly, or priming of the device.1 Patients can deliver one dose subcutaneously into the middle of the thigh.1 This may be beneficial for patients who respond inadequately to oral therapies due to lack of efficacy, experience nausea or vomiting during attacks, have gastroparesis, or delay dosing until too late into the attack.1,5,6 “We are thrilled to offer the first and only ready-to-use autoinjector for patients suffering from acute migraine and cluster headaches. Physicians are familiar with DHE, which is an effective and well-established therapy that provides sustained relief for headaches. Our single-dose autoinjector represents an innovative therapeutic option for patients that allows for quick self-administration of the medication during these painful attacks without visiting the emergency room,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty. DHE is commonly administered in emergency rooms, urgent care facilities, and headache clinics intravenously. DHE can be used at any point during a migraine attack, and may protect patients from headache recurrence.1,3,4 Approximately 39 million Americans are living with migraine7, and up to one million with cluster headache.8 Also, headache is the fourth most common reason for emergency department visits, and accounts for 3% of all emergency room visits in the United States.9 There are limited treatment options available for cluster headache, and Brekiya autoinjector represents a new treatment option for this underserved population.2 Do not take Brekiya autoinjector with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. See additional Important Safety Information below. IndicationBrekiya autoinjector is a prescription medicine used for the acute treatment of migraine with or without aura and acute cluster headaches in adults. Brekiya autoinjector is not used to prevent migraine or used to treat other types of headaches such as hemiplegic migraines (that make you unable to move on one side of your body) or basilar migraines (rare form of migraine with aura). It is not known if Brekiya autoinjector is safe and effective in children. IMPORTANT SAFETY INFORMATIONSerious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Brekiya autoinjector) with strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together. Do not use Brekiya autoinjector if you: are taking medicines known as strong CYP3A4 inhibitors, such as: ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, ketoconazole, or itraconazole.have heart problems or a history of heart problems, or uncontrolled high blood pressure.have narrowing of blood vessels in your legs, arms, stomach, or kidneys (peripheral vascular disease).have sepsis, had vascular surgery, severe liver or kidney problems.are allergic to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in Brekiya autoinjector.have taken any of the following medicines in the last 24 hours: sumatriptan, frovatriptan, ergotamine or ergotamine-type medicines, almotriptan, naratriptan, zolmitriptan, eletriptan, or rizatriptanhave taken any medicines that constrict your blood vessels or raise your blood pressure. Before you take Brekiya autoinjector, tell your healthcare provider about all your medical conditions, including if you: have high blood pressure, liver problems, or kidney problems.have risk factors for heart disease, such as: high blood pressure, high cholesterol levels, smoke, are overweight, diabetes, family history of heart disease.are pregnant or plan to become pregnant. Brekiya autoinjector may cause preterm labor. Brekiya autoinjector should be avoided during pregnancy. Talk to your healthcare provider right away if you are pregnant or want to become pregnant.are breastfeeding or plan to breastfeed. Brekiya autoinjector may reduce breast milk supply and pass into your breast milk. Brekiya autoinjector may be harmful to your baby. Do not breastfeed your baby while taking Brekiya autoinjector and for 3 days after you use Brekiya autoinjector. Talk with your healthcare provider about the best way to feed your baby if you take Brekiya autoinjector. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take: sumatriptan, ergot-type medicine, saquinavir, nefazodone, fluconazole, grapefruit juice, zileuton, nicotine, propranolol or other medicines that can lower your heart rate, any medicines that can increase your blood pressure, selective serotonin reuptake inhibitors. These are not all of the medicines that could affect how Brekiya autoinjector works. Your healthcare provider can tell you if it is safe to take Brekiya autoinjector with other medicines. How should I use Brekiya autoinjector? Certain people should take their first dose of Brekiya autoinjector in their healthcare provider’s office or in another medical setting.Brekiya autoinjector is for injection under the skin (subcutaneous) only.Use Brekiya autoinjector exactly as your healthcare provider tells you to use it.Each autoinjector contains one dose (1 mg).If your headache comes back after the first complete dose, you may give yourself up to 2 more doses as needed. Wait at least one hour between doses.Do not inject more than 3 doses (3 mg) of Brekiya autoinjector in a 24-hour period or 6 doses (6 mg) in a 1-week (7 day) period. What are the possible side effects of Brekiya autoinjector?Brekiya autoinjector can cause serious side effects, including: Heart attack and other heart problems. Heart problems may lead to death. Stop taking Brekiya autoinjector and get emergency medical help right away if you have any symptoms of a heart attack, such as: numbness or tingling in your fingers and toes, muscle pain or cramps in your arms and legs, weakness in your legs, temporary speeding or slowing of your heart rate, or swelling or itching. Brekiya autoinjector is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. Stroke. Stop using Brekiya autoinjector and get emergency medical help right away if you have any of the symptoms of a stroke.Changes in color or sensation in your fingers and toes (Raynaud’s syndrome).Stomach and intestinal problems.Increased blood pressure.Medicine overuse headache. Some people who use too much Brekiya autoinjector may make their headaches worse. If your headaches get worse, your healthcare provider may decide to stop your treatment with Brekiya autoinjector.Preterm labor.Tissue changes (fibrotic complications). Inflammation and fiber-like tissue that is not normal (fibrosis) can occur around the lungs and stomach. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Brekiya autoinjector. Call your healthcare provider for medical advice about side effects. How should I store Brekiya autoinjector? Store at room temperature between 68°F to 77°F (20°C to 25°C). Do not refrigerate or freeze.Protect Brekiya autoinjector from light.Keep Brekiya autoinjector in the original pack until ready to use. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see full Prescribing Information, including Boxed Warning, Medication Guide, and Instructions for Use at Brekiya.com. *Sustained represents a duration of approximately 24-72 hours2,3†Cluster headache results reported using IV administration.4 References: Brekiya [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2025.Data on File. Amneal Pharmaceuticals LLC.Winner P, Ricalde O, Le Force B, Saper J, Margul B. Arch Neurol. 1996;53(2):180-184.Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. Headache. 1991;31(8):525-532.Silberstein SD, Shrewsbury SB, Hoekman J. Headache. 2020;60(1):40-57. doi:10.1111/head.13700Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL. Cephalalgia. 2013;33(6):408-415.https://migraineresearchfoundation.org/about-migraine/migraine-facts/https://americanmigrainefoundation.org/resource-library/cluster-headache-2/Phelan, M, Thompson NR, Zubair A et al. Emergency department utilization among patients who receive outpatient specialty care for headache: A retrospective cohort study analysis. Headache. 2023;63:472–483. Brekiya is a registered trademark of Amneal Pharmaceuticals LLC. About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn. Cautionary Statement on Forward-Looking StatementsCertain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Investor Contact Anthony DiMeoVP, Investor Relations anthony.dimeo@amneal.comMedia ContactBrandon SkopSr. Director, Corporate CommunicationsBrandon.skop@amneal.com PP-PRS-DHE-US-0001 05/2025

Drug Approval

05 May 2025

·www.businesswire.com

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. Topline results from the study are expected in Fall 2025. “Efficient hematopoietic progenitor cell mobilization is critical for successful hematopoietic cell transplantation. Inadequate mobilization can lead to delayed transplant, multiple rounds of apheresis, and increased costs—all of which increase the burden on patients and healthcare systems,” said Jack Khouri, MD, FACP, hematologist at Cleveland Clinic and primary investigator on the trial. “GPC-100 could be transformative for patients and providers alike. We have seen effective and efficient mobilization with GPC-100 in combination with G-CSF and propranolol in our multiple myeloma patients, with an excellent safety profile. We look forward to the results of this study as we continue to evaluate GPC-100 across additional indications.” In addition to multiple myeloma, the Company is planning a Phase 1 chemosensitization study in patients with relapsed or refractory acute myeloid leukemia (AML). A previous chemosensitization trial was conducted by Taigen in China, and discussions with Key Opinion Leaders (KOLs) are underway to determine the best combination strategy to consider. The company is also exploring GPC-100’s potential applications in other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure’s pipeline following the company’s acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company’s lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit www.exicuretx.com.

Cell TherapyAcquisitionPhase 2Gene TherapyPhase 1

14 Apr 2025

·www.businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751). The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Preliminary results are encouraging, with 100% of patients achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with daratumumab. Notably, GPC-100 enabled same-day administration of the mobilizing agent and leukapheresis, offering faster kinetics compared to FDA-approved agents such as plerixafor and motixafortide, which require overnight pre-treatment. Median times to neutrophil and platelet engraftment were 11 and 14 days, respectively, which is consistent with standard of care. This trial is expected to finish patient recruitment at the end of April. About Exicure, Inc. Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. For further information, see www.exicuretx.com.

Phase 2ASHClinical ResultCell Therapy

100 Deals associated with Propranolol Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00483	Propranolol Hydrochloride	C07AA05	DB00571

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypoxia	Japan	Taiyo Pharma Co., Ltd.	18 Nov 2014
Hemangioma	United States	Pierre Fabre Médicament SAS	14 Mar 2014
Essential Hypertension	Japan	Taiyo Pharma Co., Ltd.	01 Aug 1978
Cardiomyopathy, Hypertrophic	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Coronary Artery Disease	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Essential Tremor	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Hypertension	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Migraine Disorders	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Myocardial Infarction	United States	Wyeth Pharmaceuticals LLC	13 Nov 1967
Angina Pectoris	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Atrial Fibrillation	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Atrial Premature Complexes	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Bradycardia	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Pheochromocytoma	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Tachycardia	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966
Tachycardia, Sinus	Japan	Taiyo Pharma Co., Ltd.	18 Aug 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Capillary Hemangioma	Phase 3	United States	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Australia	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Canada	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Czechia	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	France	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Germany	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Hungary	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Italy	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Lithuania	Pierre Fabre SA	01 Jan 2010
Capillary Hemangioma	Phase 3	Mexico	Pierre Fabre SA	01 Jan 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03152786 (CTgov)	Phase 2	Prostatic Cancer	46	Survey Administration+Propranolol Hydrochloride (Group I (Propranolol Hydrochloride))	vzgecsdkrc(ponpmtqtqt) = zjkskvsgue tkoyzevnef (llpvloetkg, .33) View more	-	17 Feb 2025
				Survey Administration (Group II (no Treatment))	vzgecsdkrc(ponpmtqtqt) = gbulsgtvmm tkoyzevnef (llpvloetkg, .46) View more
NCT05561751 (ASH2024) Manual	Phase 2	Multiple Myeloma CD34+	20	Propranolol+G-CSF+ Burixafor	ycxzmuoxww(omlqminlnb) = xluotbfkqw wvnkjbnfgs (slzfkhjocd )	Positive	09 Dec 2024
NCT03049306 (ProSAT, CTgov)	Phase 2	Sleep Apnea, Obstructive	24	Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet)	btrdijujby(sqdpbekvmu) = uatcvrgvsf hmvpjgiwcr (rzcrkvrfbl, 5.1) View more	-	05 Sep 2024
				Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet)	btrdijujby(sqdpbekvmu) = oereuwcycd hmvpjgiwcr (rzcrkvrfbl, 4.4) View more
ESC2024	Not Applicable	Ventricular Premature Complexes	-	Propranolol	kftxyyvwzm(nnahgbcara) = owddrmmarg ultlrrguea (wtbklwwswn, 7.7)	-	09 Apr 2024
				Propranolol (Catheter Ablation)	kftxyyvwzm(nnahgbcara) = pwzgmvrjcb ultlrrguea (wtbklwwswn, 7.7)
NCT04757584 (CTgov)	Phase 4	Heart failure with normal ejection fraction \| Heart Failure, Diastolic	9	Beta blockers (Beta Blocker ABAB Sequence)	mskktebmpk = mbqsvicryt grszynfxuu (ollxkprlvb, kwurcwtjsu - gqyufjmxop) View more	-	09 Apr 2024
				Beta blockers (Beta Blocker BABA Sequence)	mskktebmpk = foxhwaloam grszynfxuu (ollxkprlvb, egfrdxkwyk - hbehrqmqwr) View more
NCT02428205 (CTgov)	Not Applicable	Autistic Disorder \| Heart Septal Defects, Atrial	10	Propranolol (Propranolol Arm)	zzokwvmchj(yiqqsqwwwn) = snpvxsxnky cldcuiolhf (njaeeqfcqx, 14.0) View more	-	04 Mar 2024
				Placebo (Placebo Arm)	zzokwvmchj(yiqqsqwwwn) = jiesgdruyj cldcuiolhf (njaeeqfcqx, 15.6) View more
NCT02740166 (Pubmed \| Am J Gastroenterol) Manual	Phase 4	Bleeding esophageal varices cirrhosis	212	EVL plus propranolol till EEV	jtrhbktlej(irgakcwxgj) = pxztvfihid pmaahstxnt (gfaqhvxlhd ) View more	Positive	01 Feb 2024
				EVL plus continupropranolololol	jtrhbktlej(irgakcwxgj) = dssohtbdqz pmaahstxnt (gfaqhvxlhd ) View more
EADV2023	Not Applicable	Capillary Hemangioma	50	Oral propranolol	lbrnheynsu(otbaqrfzsd) = were seen only in very few cases aorlytzlgp (wkoehhaqxm )	Positive	11 Oct 2023
EUCTR2014-002018-21-IT (Pubmed \| J Hepatol)	Not Applicable	Fibrosis BH4 \| ADMA \| tHcy	-	5-MTHF+Propranolol	drsttqyeau(gyvpfembmj) = xyuvqnrzji kxeymjzkxx (hazzkvspjp, 29 - 9) View more	Positive	01 Oct 2023
				Placebo+Propranolol	xkilgcbmnz(gqnklqpyby) = pvmriryccs zefbskgemm (vfoxhmryph ) View more
NCT04299438 (PROPEL, CTgov)	Phase 3	Pregnancy, Prolonged	164	Propranolol Hydrochloride (Propranolol)	zdjgkgelym = dywvwhilpq bhykruzxhh (wzisvspdhe, wlezjqypnn - tystrpltdn) View more	-	23 Aug 2023
				Saline (Placebo)	zdjgkgelym = ewtiaktnww bhykruzxhh (wzisvspdhe, oudwozdpic - xoqapdzafd) View more